Grant of Options

RNS Number : 9700O

Futura Medical PLC

07 July 2010

 



For immediate release

7 July 2010

Futura Medical plc

("Futura" or "the Company")

Grant of Options

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, announces that on 6th July 2010 it granted options over a total of 650,000 ordinary shares of 0.2p each in the Company to Directors as detailed below.

Director	Number of options granted	Exercise price	Exercise period	Total number of options held following notification	Total number of ordinary shares held
W D Potter	100,000	40.50p	1 Aug 2012 - 31 Jul 2017	200,000	131,098
J H Barder	250,000	40.50p	1 Aug 2012 - 31 Jul 2017	450,000	745,212
D B Davies	200,000	40.50p	1 Aug 2012 - 31 Jul 2017	400,000	532,572
D A Martin	100,000	40.50p	1 Aug 2012 - 31 Jul 2017	500,000	125,000

All options were granted under the Futura Medical plc Unapproved Share Option Scheme with the exception of 176,543 options granted to each of J H Barder and D B Davies which were granted under the Futura Medical plc Enterprise Management Incentive Scheme.

The main vesting condition of the options is that the Directors remain employed with the Company as at the date of exercise.

For any further information please contact:

Futura Medical plc
James Barder, Chief Executive	Tel: [phone]
mail to: [e-mail]	www.futuramedical.com
Nomura Code Securities Limited
Phil Walker / Giles Balleny	Tel:[phone]
For media enquiries please contact:
Buchanan Communications
Mark Court / Stasa Filiplic / George Prassas	Tel: [phone]

Notes to Editors

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com

 

END

 

 

RDSLLFSIDDIDIII